RET and non-small cell lung carcinoma: For non-small cell lung cancer (NSCLC), this has led to the development of tyrosine kinase inhibitors (TKIs) specifically targeting the resulting fusion proteins, including ALK [2], ROS1 [3], RET [4], and NTRK [5].